

COVID-19: A Catalyst for Change in Telehealth Service Delivery for Opioid Use Disorder Management

NICKY MEHTANI, MD MPH JESSICA RISTAU, MD HANNAH SNYDER, MD KELLY KNIGHT, PHD



Roadmap

San Francisco's response to COVID-19

Impetus for expanding OUD Tx access during COVID-19 pandemic

Design of the "Addiction Telehealth Program" (ATP)

Data & Evaluation

Conclusions, Challenges & Policy Implications

Response to COVID-19 in San Francisco

• March 17th, 2020: Stay at Home!

Response to COVID-19 in San Francisco

• March 17th, 2020: Stay at Home! ...what about people with no home?

Response to COVID-19 in San Francisco

- March 17th, 2020: Stay at Home! ...what about people with no home?
- April 2020: Repeated outbreaks at homeless shelters, congregate living sites
 - SFDPH converts hotel rooms into temporary housing for PEH:
 - **"Isolation & Quarantine" (I&Q) Sites** □ PEH with confirmed or suspected COVID-19 (+) stay for 7-14 days
 - \circ Goal of reducing risk of COVID-19 spread.

But what about non-COVID diseases associated with poverty and isolation?

But what about non-COVID diseases associated with poverty and isolation?

San Francisco Chronicle

San Francisco homeless deaths soar — and officials say it's not directly due to COVID-19





COVID-19 is 'a crisis within a crisis' for homeless people


Homeless people are among the most vulnerable populations in the COVID-19 pandemic, yet they're largely invisible victims




San Francisco's homeless deaths have tripled. Advocates blame city neglect during pandemic

















Sources: San Francisco Department of Public Health, Harm Reduction Coalition





ATP Goal: Help PWUD tolerate I&Q stay through improved access to treatment and/or harm reduction


For OUD **Low-threshold buprenorphine via telephone visits** to patients at I&Q sites





Design of Addiction Telehealth Program (ATP)


- Pager-based telehealth program for I&Q site guests created under framework of SUD Bridge Clinic at ZSFG
 - Appointments and drop-in addiction care


- Pager "staffed" by volunteer addiction-trained physicians at UCSF
 - Monday-Friday, 8am-5pm
 - Pager # served as single access point, forwarded to on-call provider




















Data & Evaluation

- Descriptive statistics collected on case series of I&Q guests newly initiated on buprenorphine for Tx of OUD through ATP
- Between April 10th May 25th ATP consulted on **59 I&Q guests**
 - 19 patients w/ predominant opioid use
 12 Dx with OUD + initiated on buprenorphine Tx, 5 already on MOUD, 2 did not meet OUD criteria
 - Other ATP consults:
 - o 25 patients primarily using alcohol
 - 10 patients primarily using stimulants
 - o 4 patients primarily using cannabis, 1 primarily using GHB

Patient Characteristic	<u># Patients,</u>
	<u>n = 12 (%)</u>
COVID-19 Status	
Confirmed Positive	2 (17%)
Close Contact; Asymptomatic	3 (25%)
PUI; Symptomatic	7 (58%)
Housing Status	
Homeless – Unsheltered	2 (17%)
Homeless – Sheltered	9 (75%)
Incarcerated	1 (8%)
Race/Ethnicity	
Black	8 (67%)
LatinX	1 (8%)
White	4 (33%)
Sex	
Female	4 (33%)
Male	8 (67%)

Patient Characteristics	<u># Patients,</u>
	<u>n = 12 (%)</u>
Age	
30-50	10 (83%)
Over 50	2 (17%)
Prior History of MOUD	
Methadone	4 (33%)
Buprenorphine	2 (17%)
None	7 (58%)
Current Opioids Used	
Heroin	8 (67%)
Fentanyl	5 (42%)
Opioid Pain Pills	0 (0%)
Route of use	
Injection	5 (42%)
Intranasal	3 (25%)
Inhalation	4 (33%)

Patient Characteristic	<u># Patients,</u>
	<u>n = 12 (%)</u>
COVID-19 Status	
Confirmed Positive	2 (17%)
Close Contact; Asymptomatic	3 (25%)
PUI; Symptomatic	7 (58%)
Housing Status	
Homeless – Unsheltered	2 (17%)
Homeless – Sheltered	9 (75%)
Incarcerated	1 (8%)
Race/Ethnicity	
Black	8 (67%)
LatinX	1 (8%)
White	4 (33%)
Sex	
Female	4 (33%)
Male	8 (67%)

Patient Characteristics	<u># Patients,</u>
	<u>n = 12 (%)</u>
Age	
30-50	10 (83%)
Over 50	2 (17%)
Prior History of MOUD	
Methadone	4 (33%)
Buprenorphine	2 (17%)
None	7 (58%)
Current Opioids Used	
Heroin	8 (67%)
Fentanyl	5 (42%)
Opioid Pain Pills	0 (0%)
Route of use	
Injection	5 (42%)
Intranasal	3 (25%)
Inhalation	4 (33%)


Patient Characteristic	<u># Patients,</u>
	<u>n = 12 (%)</u>
COVID-19 Status	
Confirmed Positive	2 (17%)
Close Contact; Asymptomatic	3 (25%)
PUI; Symptomatic	7 (58%)
Housing Status	
Homeless – Unsheltered	2 (17%)
Homeless – Sheltered	9 (75%)
Incarcerated	1 (8%)
Race/Ethnicity	
Black	8 (67%)
LatinX	1 (8%)
White	4 (33%)
Sex	
Female	4 (33%)
Male	8 (67%)

Patient Characteristics	<u># Patients,</u>
	<u>n = 12 (%)</u>
Age	
30-50	10 (83%)
Over 50	2 (17%)
Prior History of MOUD	
Methadone	4 (33%)
Buprenorphine	2 (17%)
None	7 (58%)
Current Opioids Used	
Heroin	8 (67%)
Fentanyl	5 (42%)
Opioid Pain Pills	0 (0%)
Route of use	
Injection	5 (42%)
Intranasal	3 (25%)
Inhalation	4 (33%)

Patient Characteristic	<u># Patients,</u>
	<u>n = 12 (%)</u>
COVID-19 Status	
Confirmed Positive	2 (17%)
Close Contact; Asymptomatic	3 (25%)
PUI; Symptomatic	7 (58%)
Housing Status	
Homeless – Unsheltered	2 (17%)
Homeless – Sheltered	9 (75%)
Incarcerated	1 (8%)
Race/Ethnicity	
Black	8 (67%)
LatinX	1 (8%)
White	4 (33%)
Sex	
Female	4 (33%)
Male	8 (67%)

Patient Characteristics	<u># Patients,</u>
	<u>n = 12 (%)</u>
Age	
30-50	10 (83%)
Over 50	2 (17%)
Prior History of MOUD	
Methadone	4 (33%)
Buprenorphine	2 (17%)
None	7 (58%)
Current Opioids Used	
Heroin	8 (67%)
Fentanyl	5 (42%)
Opioid Pain Pills	0 (0%)
Route of use	
Injection	5 (42%)
Intranasal	3 (25%)
Inhalation	4 (33%)

Patient Care Cascade



Additional Findings

- *Pilot Case Series Study (n = 12 guests w/ OUD started on buprenorphine):*
 - No serious adverse events such as OD, death, or need for urgent medical services among patients started on bupe while at I&Q
 - No mention in EMR of overt displays of precipitated withdrawal.

Additional Results

- *Pilot Case Series Study (n = 12 guests w/ OUD started on buprenorphine):*
 - No serious adverse events such as OD, death, or need for urgent medical services among patients started on bupe while at I&Q
 - No mention of clear signs of precipitated withdrawal.
- To date at SF I&Q Sites (8/19/2020, n = 1898 guests total):
 - No deaths (vs. 14 deaths at SIP sites)
 - 1 overdose, successfully reversed by on-site RN Pt. Rx-ed bupe at intake but decided not to start. His girlfriend did start bupe and did not experience OD after using same fentanyl
 - <1% of recent OD deaths in SF have had buprenorphine (+) on toxicology.</p>

Conclusions

- Implementation of ATP pilot demonstrated feasibility of low-threshold, direct telehealth services to treat OUD among people staying at COVID-19 I&Q sites
- Though many patients did not follow-up at clinic post-I&Q discharge, program's harms were minimal
- ATP able to **reach high-risk patient population** that faces barriers to treatment access, including **homelessness and structural racism**.
- Majority of patients had **no prior exposure to MOUD**.

Challenges

- Must balance goals of reducing SARS-CoV-2 spread with responsible prescribing of controlled substances
- In-person exams and routine UDS can be valuable, and these are not easily attainable under current ATP model
- Telephone-based communication and multiple staffing providers is not ideal in establishing rapport with PWUD
- Not all patients with OUD staying at I&Q interested in Tx or buprenorphine.
 Telehealth programs like ATP must offer harm reduction options

Policy Implications

• ATP's success supports implementation of telehealth services for SUD management in other cities and rural areas in the U.S.

 Expansion of telehealth capabilities for OUD management temporarily permitted by DEA (including initiating buprenorphine via telephonic visits) is an equity issue and should remain available in the post-COVID era.

